The four lawsuits scheduled for bellwether trial were pushed back another month, at the request of both parties.
The trials, which were initially set to begin in February 2017 in New Orleans, were previously rescheduled to begin in March. Now, the first trial will begin in April, with the other three cases following in May, June, and July 2017.
Xarelto Trial Schedule
District Judge Eldon E. Fallon issued Case Management Order 2D on January 30, which sets out the trial schedule as follows:
• Bordreaux, Jr. et al v. Janssen Research & Development LLC et al – April 27 in the Eastern District of Louisiana
• Orr et al v. Janssen Research & Development LLC et al – May 30 in the Eastern District of Louisiana
• Mingo v. Janssen Research & Development LLC et al – June 2017 (date not yet determined) in the Southern District of Mississippi
• Henry v. Janssen Research & Development LLC et al – July 2017 (date not yet determined) in the Northern District of Texas
Over 15,000 cases are currently pending in the Xarelto multidistrict litigation (MDL) in the Eastern District of Louisiana.
What is Xarelto?
The U.S. Food and Drug Administration (FDA) approved Xarelto in November 2011 as a more convenient alternative to Coumadin (warfarin), the traditional blood thinner that has been used since the 1950s to prevent heart attacks, strokes, and blood clots.
Although all blood thinners increase the risk of bleeding problems, Xarelto has been linked to an increased number of uncontrollable blood injuries, mostly because there is no approved antidote available for patients who use the medication, and many of the side effects have been severe because the bleeding cannot be effectively controlled.